End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
39.2 TWD | +1.29% | +3.16% | -39.78% |
May. 28 | Tanvex BioPharma, Inc.(TWSE:6541) dropped from S&P Global BMI Index | CI |
May. 13 | Tanvex BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2022 | 22.4 725.24 | Sales 2023 | 61.41 1.99K | Capitalization | 8.71B 282B |
---|---|---|---|---|---|
Net income 2022 | -1.64B -53.12B | Net income 2023 | -2.14B -69.18B | EV / Sales 2022 | 599,427,887 x |
Net Debt 2022 | 1.05B 34.09B | Net Debt 2023 | 1.35B 43.73B | EV / Sales 2023 | 163,906,538 x |
P/E ratio 2022 |
-7.54
x | P/E ratio 2023 |
-3.93
x | Employees | 167 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 59.81% |
1 day | +1.29% | ||
1 week | +3.16% | ||
1 month | -13.94% | ||
3 months | -36.67% | ||
6 months | -44.63% | ||
Current year | -39.78% |
Managers | Title | Age | Since |
---|---|---|---|
Kuan Hao Lin
DFI | Director of Finance/CFO | - | 22-02-17 |
Members of the board | Title | Age | Since |
---|---|---|---|
ALLEN Chao
FOU | Founder | 78 | 13-05-07 |
Ta Meng Tseng
BRD | Director/Board Member | 66 | 13-10-05 |
Chih Chuan Chen
BRD | Director/Board Member | - | 13-10-05 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 7 M€ | +0.11% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 39.2 | +1.29% | 83,819 |
24-05-30 | 38.7 | +0.91% | 79,029 |
24-05-29 | 38.35 | -1.67% | 105,765 |
24-05-28 | 39 | +1.17% | 92,493 |
24-05-27 | 38.55 | +1.45% | 74,276 |
End-of-day quote Taiwan S.E., May 30, 2024
More quotes1st Jan change | Capi. | |
---|---|---|
-39.78% | 198M | |
+13.69% | 118B | |
+12.96% | 106B | |
-2.74% | 24.28B | |
+0.84% | 21.96B | |
-9.37% | 18.16B | |
-42.12% | 16.37B | |
-17.74% | 15.56B | |
+4.94% | 13.63B | |
+31.64% | 12.27B |
- Stock Market
- Equities
- 6541 Stock